It was immediately suggested that the majority of the antitumor effects caused by STING activation depend upon production of IFN-β by antigen-presenting cells (APCs) that promotes CD8+ T cell priming against tumor-associated antigens (Klarquist et al. 2014; Woo et al. 2014). This evidence concerns the gene STING1 and neoplasm.